Hepatitis D Virus Co-Infection

Overview

Plain-Language Overview

Hepatitis D Virus Co-Infection is a liver infection that occurs only in people who already have Hepatitis B Virus (HBV). It affects the liver, causing inflammation and damage that can lead to serious health problems like liver failure or cirrhosis. This infection is caused by the Hepatitis D Virus (HDV), which needs the presence of HBV to replicate. People with this co-infection often experience more severe symptoms than those with HBV alone. The main health impact is on the liver’s ability to function properly, which can affect overall health and quality of life.

Clinical Definition

Hepatitis D Virus Co-Infection is defined as simultaneous infection with Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV), where HDV requires the HBV surface antigen (HBsAg) for viral assembly and propagation. The core pathology involves HDV-induced hepatocellular injury mediated by immune responses against infected hepatocytes. This co-infection typically results in a more aggressive clinical course than HBV infection alone, with increased risk of fulminant hepatitis, rapid progression to cirrhosis, and higher rates of hepatocellular carcinoma. The mechanism involves HDV using HBV’s envelope proteins to infect hepatocytes, leading to enhanced liver inflammation and damage. Clinically, patients may present with jaundice, elevated transaminases, and signs of acute or chronic liver disease. The co-infection is epidemiologically significant in areas with high HBV prevalence and is a major cause of severe viral hepatitis worldwide.

Inciting Event

Exposure to HDV via blood or body fluids in a person already infected with HBV triggers co-infection.
Superinfection of chronic HBV carriers with HDV leads to acute exacerbation of liver disease.
Needle sharing or unsafe injection practices facilitate HDV transmission.
Sexual contact with an HDV-infected individual can initiate co-infection.

Latency Period

Incubation period ranges from 3 to 7 weeks after exposure before symptoms develop.
Symptoms typically appear within 2 months of HDV infection in co-infected patients.
Chronic HDV infection may remain asymptomatic for years before liver damage manifests.
Rapid progression to cirrhosis can occur within 5 to 10 years in chronic HDV infection.

Diagnostic Delay

Lack of routine HDV testing in HBV-infected patients leads to underdiagnosis.
Overlap of symptoms with HBV mono-infection causes misattribution of liver disease.
Low clinical suspicion in non-endemic areas delays diagnosis.
Serologic testing for anti-HDV antibodies is not always performed in chronic hepatitis B patients.

Clinical Presentation

Signs & Symptoms

Fatigue and malaise due to systemic viral infection
Jaundice from impaired bilirubin metabolism
Right upper quadrant abdominal pain from liver inflammation
Anorexia and nausea common in acute hepatitis
Dark urine and pale stools due to cholestasis

History of Present Illness

Acute co-infection presents with abrupt onset of jaundice, fatigue, and right upper quadrant pain.
Superinfection in chronic HBV carriers often causes worsening of baseline symptoms and hepatic decompensation.
Symptoms of chronic HDV include progressive fatigue, hepatomegaly, and signs of portal hypertension.
Patients may report recent high-risk exposures such as intravenous drug use or unprotected sex.

Past Medical History

Known chronic hepatitis B infection is the most important relevant history.
History of intravenous drug use or blood transfusions increases risk of HDV co-infection.
Previous episodes of acute hepatitis or liver dysfunction may suggest prior viral hepatitis.
Immunosuppressive conditions or therapies can worsen disease progression.

Family History

Family members with chronic hepatitis B infection increase risk of HDV exposure.
No direct genetic inheritance of HDV infection, but familial clustering due to shared risk factors.
Family history of liver cirrhosis or hepatocellular carcinoma may be relevant in chronic viral hepatitis.
[]

Physical Exam Findings

Jaundice with yellowing of the sclera and skin due to hyperbilirubinemia
Hepatomegaly indicating liver inflammation or swelling
Right upper quadrant tenderness on palpation reflecting hepatic inflammation
Spider angiomas and palmar erythema in chronic liver disease
Ascites in advanced liver dysfunction or cirrhosis

Diagnostic Workup

Diagnostic Criteria

Diagnosis of Hepatitis D Virus Co-Infection requires detection of HBsAg indicating active HBV infection, along with serologic evidence of HDV infection such as anti-HDV antibodies (IgM or IgG) and/or HDV RNA by PCR. Elevated liver enzymes (ALT and AST) support active liver inflammation. Confirmatory diagnosis relies on detecting HDV RNA in serum, which indicates active viral replication. The presence of both HBV and HDV markers in a patient with clinical or biochemical evidence of hepatitis confirms the co-infection.

Pathophysiology

Key Mechanisms

HDV requires hepatitis B virus (HBV) surface antigen (HBsAg) for viral assembly and propagation, leading to co-infection or superinfection scenarios.
Direct cytopathic effect of HDV on hepatocytes causes liver inflammation and damage.
Immune-mediated hepatocyte injury triggered by the host response to HDV infection exacerbates liver injury.
Suppression of HBV replication by HDV can alter the clinical course and viral dynamics.
Rapid progression to liver fibrosis and cirrhosis due to chronic inflammation induced by HDV.

Involvement	Details
Organs	Liver is the primary organ affected by HDV co-infection, leading to hepatitis, fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma.
Tissues	Liver parenchyma undergoes inflammation, necrosis, and fibrosis due to HDV-induced immune-mediated injury.
Cells	Hepatocytes are the primary target cells for HDV infection and replication, leading to liver injury.
	Kupffer cells contribute to the inflammatory response and cytokine production in HDV co-infection.
	Cytotoxic T lymphocytes mediate immune-mediated hepatocyte damage during HDV infection.
Chemical Mediators	Interferon-alpha is a key antiviral cytokine used therapeutically to suppress HDV replication.
	Tumor necrosis factor-alpha (TNF-α) is elevated during liver inflammation and contributes to hepatocyte injury.
	Alanine aminotransferase (ALT) is a biochemical marker indicating hepatocellular damage in HDV co-infection.

Treatments

Pharmacological Treatments

Pegylated Interferon-alpha
- Mechanism:
  - Enhances the host immune response to suppress HDV replication and modulate antiviral activity.
- Side effects:
  - Flu-like symptoms
  - Depression
  - Cytopenias
  - Thyroid dysfunction
- Clinical role:
  - First-line

Non-pharmacological Treatments

Regular monitoring of liver function tests and HDV RNA levels to assess disease progression and treatment response.
Avoidance of alcohol and hepatotoxic drugs to reduce further liver injury.
Screening and vaccination of close contacts for hepatitis B virus to prevent co-infection.

Prevention

Pharmacological Prevention

Hepatitis B vaccination prevents HBV infection and thus HDV co-infection
No specific antiviral therapy is approved for HDV prevention beyond HBV control
Pegylated interferon-alpha may reduce HDV replication but is not preventive
Antiviral agents targeting HBV replication indirectly reduce HDV risk

Non-pharmacological Prevention

Safe sex practices to reduce HBV/HDV transmission
Screening blood products to prevent parenteral transmission
Avoidance of intravenous drug use to reduce bloodborne infection risk
Education on perinatal transmission prevention in HBV-infected mothers
Regular monitoring of HBV-infected patients to detect HDV co-infection early

Outcome & Complications

Complications

Fulminant hepatitis with rapid liver failure
Progression to cirrhosis with portal hypertension
Hepatocellular carcinoma development in chronic infection
Hepatic decompensation including ascites and encephalopathy
Increased mortality compared to HBV infection alone

Short-term Sequelae	Long-term Sequelae
Acute hepatitis flare with marked elevation of liver enzymes Cholestatic hepatitis causing severe jaundice and pruritus Coagulopathy due to impaired liver synthetic function Hepatic encephalopathy in severe acute liver injury Systemic symptoms such as fever and malaise	Chronic hepatitis D infection leading to persistent liver inflammation Cirrhosis with fibrosis and architectural distortion of the liver Portal hypertension causing variceal bleeding and splenomegaly Hepatocellular carcinoma as a late complication Liver failure requiring transplantation

Differential Diagnoses

Hepatitis D Virus Co-Infection versus Hepatitis B Virus (HBV) Monoinfection

Hepatitis D Virus Co-Infection	Hepatitis B Virus (HBV) Monoinfection
Positive HBsAg with detectable HDV RNA or anti-HDV antibodies	Positive HBsAg without detectable HDV RNA or anti-HDV antibodies
More severe acute hepatitis and rapid progression to cirrhosis due to HDV co-infection	Typically slower progression to chronic liver disease without superimposed acute severe hepatitis
Poor response to HBV antivirals alone; requires additional management targeting HDV	Responds to nucleos(t)ide analogs targeting HBV replication

Hepatitis D Virus Co-Infection versus Hepatitis C Virus (HCV) Infection

Hepatitis D Virus Co-Infection	Hepatitis C Virus (HCV) Infection
Defective single-stranded RNA virus requiring HBV for replication	Single-stranded RNA virus of the Flaviviridae family
Requires HBV co-infection; transmitted similarly but only infects with HBV presence	Commonly transmitted via intravenous drug use and blood transfusions
Positive HDV RNA and HBV surface antigen	Positive HCV RNA PCR with negative HBV markers

Hepatitis D Virus Co-Infection versus Autoimmune Hepatitis

Hepatitis D Virus Co-Infection	Autoimmune Hepatitis
Positive viral serologies for HBV and HDV without autoimmune markers	Elevated ANA, SMA, and hypergammaglobulinemia
Acute or chronic hepatitis with viral replication markers, poor response to immunosuppression alone	Chronic progressive hepatitis with fluctuating transaminases and response to immunosuppression
Liver biopsy may show viral cytopathic changes and HDV antigen presence	Liver biopsy showing interface hepatitis with plasma cell infiltrate without viral inclusions

Hepatitis D Virus Co-Infection versus Wilson Disease

Hepatitis D Virus Co-Infection	Wilson Disease
Can present at any age but often in adults with HBV/HDV exposure	Typically presents in adolescents or young adults
Normal ceruloplasmin with positive viral serologies	Low serum ceruloplasmin and elevated 24-hour urinary copper
No Kayser-Fleischer rings; positive HDV RNA and HBV surface antigen	Kayser-Fleischer rings on slit-lamp exam and ATP7B gene mutation

Hepatitis D Virus Co-Infection versus Alcoholic Hepatitis

Hepatitis D Virus Co-Infection	Alcoholic Hepatitis
History of HBV exposure and risk factors for viral hepatitis	History of chronic heavy alcohol use
Elevated ALT and AST with variable ratio, positive viral serologies	Elevated AST > ALT with AST:ALT ratio >2, elevated GGT
Progressive liver injury driven by viral replication and immune-mediated damage	Often acute-on-chronic liver injury with potential for improvement after alcohol cessation